Krystal Biotech, Inc. Stock Analysis & AI Score
Krystal Biotech, Inc. (KRYS) has an ST Score of 64.5 (B), driven by its Profitability (A+) and held back by its Valuation (F). Analysts rate it Buy with a $395.20 price target (+20.7% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Krystal Biotech, Inc. (KRYS) has an ST Score of 64.5 (B), driven by its Profitability (A+) and held back by its Valuation (F). Analysts rate it Buy with a $395.20 price target (+20.7% upside).
- Strongest
- ProfitabilityA+
- Weakest
- ValuationF
All factor grades
- ProfitabilityA+
- MomentumA
- Financial StrengthA-
- GrowthB+
- ForecastB-
- ValuationF
- Piotroski5/9
Contact
KRYS stock: frequently asked questions
What is KRYS's ST Score?
Krystal Biotech, Inc. (KRYS) has an ST Score of 64.5 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is KRYS a buy, hold, or sell?
Analysts rate KRYS a Buy, with a price target of $395.20 (+20.7% vs the current price). Our ST Score grades it B (64.5/100). The ST Score is a data-driven signal, not a recommendation.
What are KRYS's factor grades?
Valuation F, Profitability A+, Financial Strength A-, Momentum A, Growth B+, Forecast B-.
What is KRYS's valuation grade?
Krystal Biotech, Inc. (KRYS) earns a valuation grade of F, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is KRYS's growth grade?
Krystal Biotech, Inc. (KRYS) earns a growth grade of B+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is KRYS's profitability grade?
Krystal Biotech, Inc. (KRYS) earns a profitability grade of A+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is KRYS's financial strength grade?
Krystal Biotech, Inc. (KRYS) earns a financial strength grade of A-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for KRYS?
The average analyst price target for Krystal Biotech, Inc. (KRYS) is $395.20 from 17 analysts, which is +20.7% versus the recent price of $327.30.
What is KRYS's Piotroski score?
Krystal Biotech, Inc. (KRYS) has a Piotroski F-Score of 5 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.